Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Vogenx initiated EMERGE (NCT07760961), a Phase 2b randomized, placebo-controlled trial of mizagliflozin in post-bariatric hypoglycemia, enrolling approximately 36 adults across roughly 10 US sites. Participants will receive mizagliflozin 5 mg or 10 mg or placebo three times daily for 28 days, with the primary endpoint being combined Level 2 and Level 3 hypoglycemic events.
Key figures
- Drug Name
- mizagliflozin
- Phase Of Trial
- Phase 2b
- Trial name
- EMERGE (VGX-001-013)
- Dosing arms
- ["mizagliflozin 5 mg TID","mizagliflozin 10 mg TID","placebo TID for 28 days"]
- Trial sites
- approximately 10 US sites
- Primary endpoint
- number of combined Level 2 and Level 3 hypoglycemic events
- Trial identifier
- NCT07760961
- Planned enrollment
- 36
- Prior subject exposure
- more than 500 subjects across 10 clinical studies
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.